GlassScriptPhysician profile
Ronald N Daoud
NPI 1093732992
$15,361.34
in general payments reported to CMS, 2019-2025
75 companies · $2,854 in 2025
The $2,854 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,243 · 2020: $1,596 · 2021: $2,908 · 2022: $1,775 · 2023: $2,406 · 2024: $1,579 · 2025: $2,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,838.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,369.69 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $1,103.23 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,038.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $777.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $726.77 | 2019-2024 | |
| Lilly USA, LLC | $721.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $706.98 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $681.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $652.13 | 2019-2024 | Gattex, Trintellix |
| Amgen INC. | $648.74 | 2020-2025 | Repatha, Otezla, Otezla |
| Radius Health, INC. | $508.42 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $500.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.75 | 2019-2025 | Jardiance |
| Abbott Laboratories | $442.70 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $321.14 | 2019-2020 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.